Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
Not Applicable (2)
P 1 (3)
P 2 (1)

Trial Status

Recruiting3
Active Not Recruiting2
Not Yet Recruiting2

Clinical Trials (7)

Showing 7 of 7 trials
NCT07038369Phase 1Active Not Recruiting

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT06129604Phase 2Active Not Recruiting

Pilot Window of Opportunity Trial (POET)

NCT07675733Not ApplicableNot Yet RecruitingPrimary

A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility

NCT07374809Not ApplicableNot Yet RecruitingPrimary

IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER

NCT07070518Phase 1Recruiting

Study of GV20-0251 in Participants With Solid Tumor Malignancies

NCT06893861RecruitingPrimary

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

NCT05669430Phase 1Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Showing all 7 trials

Research Network

Activity Timeline